XML 27 R15.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2024

8. Goodwill and Intangible Assets

As of March 31, 2024 and December 31, 2023, the Company’s goodwill balance was $133,857. The Company’s goodwill resulted from the acquisition of BioDelivery Sciences International, Inc. (“BDSI”) on March 22, 2022 (the “BDSI Acquisition”).

The following table sets forth the cost, accumulated amortization, and carrying amount of intangible assets as of March 31, 2024 and December 31, 2023:


	March 31, 2024						December 31, 2023
		Cost		Accumulated Amortization		Carrying Amount		Cost		Accumulated Amortization		Carrying Amount
Belbuca	$	360,000	$	(152,669)	$	207,331	$	360,000	$	(133,821)	$	226,179
Nucynta Products		521,170		(396,555)		124,615		521,170		(382,710)		138,460
Symproic		70,000		(14,755)		55,245		70,000		(12,931)		57,069
Total intangible assets	$	951,170	$	(563,979)	$	387,191	$	951,170	$	(529,462)	$	421,708

The following table presents amortization expense recognized in cost of product revenues for the three months ended March 31, 2024 and 2023:


	Three Months Ended March 31,
		2024		2023
Belbuca	$	18,848	$	18,849
Nucynta Products		13,845		16,796
Symproic		1,824		1,821
Total amortization expense	$	34,517	$	37,466

As of March 31, 2024, the remaining amortization expense expected to be recognized is as follows:


Years ended December 31,	Belbuca		Nucynta Products		Symproic		Total
2024	$	56,545	$	41,539	$	5,461	$	103,545
2025		75,393		55,384		7,285		138,062
2026		75,393		27,692		7,285		110,370
2027		—		—		7,285		7,285
2028		—		—		7,285		7,285
Thereafter		—		—		20,644		20,644
Remaining amortization expense	$	207,331	$	124,615	$	55,245	$	387,191